Our Clinical Focus 2018-01-09T10:01:47+00:00

With the discovery of the innate repair receptor (IRR), Araim has identified a target for activating tissue repair and recovery from inflammation and other injuries. Our lead compound, cibinetide, a first-in-class synthetic peptide, is being developed to help address devastating injuries and chronic diseases underserved by current therapies, through its activation of this platform technology.

Our near-term clinical development program is focused on evaluating the ability of cibinetide to improve the lives of patients suffering from neuropathic and retinal diseases, where the underlying pathophysiological drivers of disease—insufficient control of inflammatory signaling, insufficient activation of repair processes—remain ongoing and active. Our development program is most advanced in neuropathic pain and disease modification indications, both in sarcoidosis and in diabetes.

cibinetide has been granted 4 orphan designations, including US and EU orphan designation for the treatment of sarcoidosis, US orphan and fast track designation for the treatment of neuropathic pain in sarcoidosis, and US orphan designation for treatment to increase survival and improve functioning of pancreatic islet cells following transplantation.

cibinetide pipeline

Inflammation and nerve damage can result from disease or trauma. A number of disease types can cause nerve damage (neuropathy), including systemic diseases such as diabetes and chronic kidney disease, as well as infections and autoimmune disorders such as rheumatoid arthritis and sarcoidosis.

Neuropathy is very common. It is estimated that 25% to 30% of all Americans will be affected by a neuropathy and 65% to 70% patients with diabetes have neuropathy.

There are no FDA-approved treatments that regrow nerve tissue or improve nerve function, the root cause of neuropathy.

Current treatment options for neuropathy focus solely on treating the painful symptoms of neuropathy: burning, tingling, pressure, severe pain. However, these agents do not inhibit, delay, or repair the actual nerve damage.

A significant opportunity remains to address the underlying cause of neuropathy, specifically to modify the course of the disease, through regeneration of nerve tissue.

ARA 290 is a novel, first-in-class treatment, currently in clinical development to assess its safety and efficacy in patients with neuropathic conditions.